Clinical Trials Logo

Opioid-Related Disorders clinical trials

View clinical trials related to Opioid-Related Disorders.

Filter by:

NCT ID: NCT00000353 Completed - Clinical trials for Substance-Related Disorders

Trial of Buprenorphine/Naloxone for Opiate Dependence - 2

Start date: October 1996
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of a buprenorphine/naloxone sublingual tablet formulation as an office-based therapy for opiate dependence treatment.

NCT ID: NCT00000352 Completed - Clinical trials for Substance-Related Disorders

Effects of Dextromethorphan on Opioid Tolerance in Methadone Patients - 1

Start date: December 1996
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if addition of dextromethorphan to a stable dose of methadone in opioid dependent subjects will significantly affect physical and psychological aspects of opioid tolerance.

NCT ID: NCT00000345 Completed - Clinical trials for Opioid-Related Disorders

Evaluation of Lofexidine for Treatment of Opiate Withdrawal - 10

Start date: April 1996
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety of lofexidine in the treatment of opiate-dependent individuals.

NCT ID: NCT00000344 Completed - Clinical trials for Opioid-Related Disorders

Buprenorphine/Naloxone for Treatment of Opiate Dependence - 9

Start date: n/a
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of a buprenorphine/naloxone sublingual tablet formulation as an office-based therapy for opiate-dependence treatment.

NCT ID: NCT00000341 Completed - Clinical trials for Opioid-Related Disorders

Evaluation of Liquid vs. Tablet Buprenorphine - 6

Start date: August 1996
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the steady-state pharmacokinetics and bioavailability of buprenorphine sublingual tablets vs. sublingual solution.

NCT ID: NCT00000335 Completed - Clinical trials for Opioid-Related Disorders

Activity Monitoring Assessment of Opiate Withdrawal - 4

Start date: September 30, 1995
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if hyperactivity accompanies abrupt opiate withdrawal in heroin addicts, to determine if computerized solid state activity monitors are capable of quantifying hyperactivity, and to quantify the physical and affective symptoms occurring during abrupt withdrawal in heroin addicts and morphine's capacity to alleviate these symptoms.

NCT ID: NCT00000334 Completed - Clinical trials for Opioid-Related Disorders

Comparison of Buprenorphine and Methadone - 3

Start date: December 1, 2002
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare agonist and antagonist profile associated with buprenorphine vs. methadone during opiate withdrawal.

NCT ID: NCT00000320 Completed - Clinical trials for Opioid-Related Disorders

Buprenorphine Formulation Comparison: Sublingual Tablet vs. Solution - 1

Start date: October 1997
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to compare subject response to liquid vs. tablet formulations, to assess bioequivalency of liquid vs. tablet, to compare subject preference, and to evaluate if dose response curve for tablet is equal to liquid form."

NCT ID: NCT00000319 Completed - Clinical trials for Substance-Related Disorders

Buprenorphine Maintenance Dose Schedule and Treatment Setting - 2

Start date: June 1996
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of treating opioid-dependent individuals with buprenorphine on a thrice-weekly schedule compared to daily dosing.

NCT ID: NCT00000318 Completed - Clinical trials for Substance-Related Disorders

Buprenorphine Maintenance Dose Schedule and Treatment Setting - 1

Start date: December 1994
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess optimal dosage of buprenorphine on a thrice weekly schedule in a pilot clinical trial.